- Home
- APLT vs SLGB Comparison
APLT vs SLGB Comparison
Compare APLT & SLGB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- SLGB
- Stock Information
- Founded
- APLT 2016
- SLGB 2017
- Country
- APLT United States
- SLGB Hong Kong
- Employees
- APLT N/A
- SLGB N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- SLGB Integrated Freight & Logistics
- Sector
- APLT Health Care
- SLGB Industrials
- Exchange
- APLT Nasdaq
- SLGB Nasdaq
- Market Cap
- APLT 178.6M
- SLGB 144.3M
- IPO Year
- APLT 2019
- SLGB 2025
- Fundamental
- Price
- APLT $1.28
- SLGB $2.99
- Analyst Decision
- APLT Buy
- SLGB
- Analyst Count
- APLT 5
- SLGB 0
- Target Price
- APLT $4.13
- SLGB N/A
- AVG Volume (30 Days)
- APLT 5.5M
- SLGB 2.1M
- Earning Date
- APLT 11-10-2025
- SLGB 11-16-2025
- Dividend Yield
- APLT N/A
- SLGB N/A
- EPS Growth
- APLT N/A
- SLGB N/A
- EPS
- APLT N/A
- SLGB 0.03
- Revenue
- APLT $121,000.00
- SLGB $92,917,774.00
- Revenue This Year
- APLT N/A
- SLGB N/A
- Revenue Next Year
- APLT $5,935.35
- SLGB N/A
- P/E Ratio
- APLT N/A
- SLGB $101.24
- Revenue Growth
- APLT N/A
- SLGB N/A
- 52 Week Low
- APLT $0.30
- SLGB $2.42
- 52 Week High
- APLT $10.62
- SLGB $6.08
- Technical
- Relative Strength Index (RSI)
- APLT 60.36
- SLGB N/A
- Support Level
- APLT $1.16
- SLGB N/A
- Resistance Level
- APLT $1.50
- SLGB N/A
- Average True Range (ATR)
- APLT 0.14
- SLGB 0.00
- MACD
- APLT -0.02
- SLGB 0.00
- Stochastic Oscillator
- APLT 61.64
- SLGB 0.00
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.